June 16, 2025
StemRIM Inc.

StemRIM Announces Publication of a Paper on Redasemtide (HMGB1 Fragment Peptide) for Liver Cirrhosis

Osaka, Japan, June 16, 2025 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “StemRIM”) announces that a recent study conducted by Niigata University has been published in the international journal Biochemistry and Biophysics Reports. The study reports that Redasemtide (HMGB1 fragment peptide), currently under development by our company, demonstrates multifaceted therapeutic effects against liver diseases.

Title	:	Multidirectional therapeutic effects of synthesized HMGB1 peptide on liver cirrhosis in mice
Journal	:	Biochemistry and Biophysics Reports
Publication Date	:	May 2025
URL	:	https://doi.org/10.1016/j.bbrep.2025.102061

The findings of this study demonstrate that a single synthetic peptide can exert comprehensive therapeutic effects on the complex pathological conditions associated with liver cirrhosis, including lipid metabolism disorders, chronic inflammation, and liver fibrosis. For further details, please refer to the full article.

Guided by our mission to "Overcomming Intractable diseases with "Regeneration-Inducing Medicine™"" we remain committed to advancing "Regeneration-Inducing Medicine™" as innovative therapeutic solutions for patients suffering from intractable diseases.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration.

Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with ectomesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
X: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)